BlinkLab Selected for Morocco’s Nationwide Government-Funded Autism Screening Program

Highlights

• Government-Led National Program in Morocco: BlinkLab’s flagship Dx 1 test has been selected to support the Kingdom of Morocco’s nationwide early autism screening initiative under a formal, multi-ministry national framework, pursuant to the High Instructions of His Majesty King Mohammed VI.
• Nationwide Early Screening: Systematic early screening will be implemented throughout the entire Kingdom of Morocco, starting at 18 months of age. Through this program, Morocco aims to establish itself as an international leader in early autism diagnosis, intervention and care.
• Large-Scale Public Health Need: In Morocco, approximately 600,000 children are born annually, with Moroccan authorities estimating that autism currently affects more than 400,000 people nationally.
• Government-Funded Implementation: All costs for clinical rollout and clinical implementation will be funded by the Moroccan government and the Foundation Mohammed V for Solidarity. Blinklab will own the data generated by the programme.
• AI-Enabled Health Equity and Alignment with International Standards: National deployment in Morocco provides a real-world framework to assess how technology-enabled approaches can support early autism screening at scale. The program is implemented according to internationally recognised standards and approaches, including those acknowledged by organisations such as the World Health Organization (WHO), to support scalability and equitable access across regions.
• Strategic Significance for BlinkLab: Government-funded national deployment in Morocco will drive large-scale adoption of the BlinkLab’s Dx1 technology and real-world validation ahead of any future FDA clearance, with commercial terms to be revisited post-approval.
• Recognition of BlinkLab Leadership: The autism screening initiative will include the establishment of a Center of Excellence for Autism Research, Education and Training. Dr Henk-Jan Boele (BlinkLab Managing Director & CEO) and Prof Abdeslem El Idrissi (BlinkLab Scientific Board) will join a consortium of experts for the Center.

BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”) is pleased to announce its involvementin a landmark national autism screening and capacity-building initiative launched by the Kingdom of Morocco. This initiative is the first and most comprehensive of its kind worldwide, positioning Morocco as a leading example for the international community. With the launch of its government led national autism screening program, Morocco intends to set a global precedent in autism screening.

BlinkLab’s flagship technology will be integrated into a nationwide screening programme for autism, targeting children from 18 months of age. To facilitate the programme, a new Center of Excellence for Autism Research, Education and Training will be created in the Kingdom of Morocco. Dr Henk-Jan Boele (BlinkLab’s Managing Director & CEO) and Prof Abdeslem El Idrissi (BlinkLab’s Scientific Advisor) will have advisory roles and will be part of a consortium of experts in the field.

About the National Autism Screening and Training Framework

The national screening program is being launched pursuant to the High Instructions of His Majesty King Mohammed VI and reflects Morocco’s national commitment to equitable access to healthcare, education, and social services for persons with disabilities. The nationwide initiative is governed by a formal national framework convention, signed in Rabat on 29 August 2025, between:

• Foundation Mohammed V for Solidarity
• Ministry of Higher Education, Scientific Research, and Innovation
• Ministry of Health and Social Protection; and
• Ministry of Solidarity, Social Integration, and the Family

referred to hereafter as (the “Convention”).

As a result of the Convention, BlinkLab has entered into a separate agreement with the FoundationMohammed V for Solidarity (“the Foundation”) (“Agreement”).

The Convention framework establishes a coordinated national program to strengthen autism and broader neurodevelopmental care across Morocco. The initiative includes systematic early autism screening commencing from 18 months of age, the integration of validated digital screening tools across primary care, community and specialist settings, and the development of a specialised clinical training program in Applied Behaviour Analysis (ABA). The Foundation will play a central role in the national rollout. The Foundation is the founder and principal supporter of the Mohammed VI National Center for the Disabled (CNMH), through which autism diagnostic evaluations using BlinkLab’s technology will be conducted. BlinkLab has been collaborating closely with CNMH in multi-centre clinical studies for several years.¹ CNMH and its affiliated centres form part of a broad national clinical network with strong international bilateral collaborations, including several Gulf States.

BlinkLab’s Role and Reference Positioning

In line with one of Morocco’s Ministry of Health and Social Protection’s commitments to systematic early screening for autism, one of the central components of the Convention framework is the planned establishment of an early screening program from the age of 18 months in children, which will be implemented across regions of the Kingdom of Morocco in both outpatient and hospital settings. Morocco has a population of 38M people, with approximately ~600,000 children born annually (cf. Australia, ~290,000 births annually). Moroccan authorities estimate that autism affects more than 400,000 people nationally.

BlinkLab will support the initiative through the integration of its clinically-validated, smartphone-based digital autism technology within Morocco’s national screening program. The Foundation Mohammed V for Solidarity selected BlinkLab based on successful collaborations in earlier clinical studies, including the Company’s large-scale multi-centre study in collaboration with the Mohammed VI National Center for the Disabled in Morocco,² which also led to the recent peer-reviewed publication in Autism Research^3,4.

These studies demonstrated the effectiveness of BlinkLab’s non-invasive digital approach in enabling rapid, standardised, and objective detection of autism-related neurometric features. Building on this evidence, the Moroccan government and the Foundation consider BlinkLab’s objective neurometric biomarkers suitable for deployment across a range of healthcare and community settings nationwide. BlinkLab’s assessments are intended to function as an adjunctive digital aid rather than a stand-alone diagnostic tool, and will be used alongside established screening questionnaires. As with these questionnaire-based methods, which are not regulated as medical devices, BlinkLab’s assessments are designed to be non-invasive and low risk, supporting their use in broad, real-world screening contexts. The BlinkLab tests will be rolled out in public primary care settings. There are approximately 3,000 of these public primary healthcare centers in Morocco.⁵ Initial screening centres will commence operations from April 2026, with phased national expansion thereafter.

Reference positioning for BlinkLab’s contribution in the initiative is anchored in the Convention framework’s emphasis on the use of emerging new technologies, as well as universal approaches to screening. These initiatives are fully aligned with guidelines and recommendations recognised by the World Health Organization (WHO), as well as the national objectives set out by Morocco for the improvement of equitable access to services for people with disabilities and neurodevelopmental disorders.

Brian Leedman, Non-executive Chairman of BlinkLab, commented:

“The deployment of Blinklab’s smartphone technology as an early screening test for autism prior to regulatory approval is testament to the commercial possibilities of the Dx 1 platform. Early screening leads to early diagnosis and early intervention for families seeking support for children with developmental and behavioural difficulties. There is clear evidence that early intervention programs improve clinical outcomes and are highly cost-effective during adulthood. Morocco’s actions will serve notice to governments globally seeking to maximise the effectiveness of their healthcare systems. In relation to Australia’s own NDIS, an adult receives more than three times the level of funding support than a child.⁶ This represents a tsunami of funding to support the current wave of children being diagnosed with autism growing into adulthood.”

Dr Henk-Jan Boele, Managing Director and CEO of BlinkLab, stated:

“BlinkLab is honoured to support this important national initiative in Morocco to improve autism diagnosis and ongoing care. The CNMH autism centres in Morocco have extensive first-hand experience with our technology through prior collaborative clinical studies. This direct clinical experience, highlighted BlinkLab’s operational ease of use and its high diagnostic accuracy, which in turn, drove the government’s decision to select BlinkLab’s Dx1 Platform for its nationwide screening program. It reflects high levels of confidence in our platform capacities, even prior to formal regulatory clearance. This outcome also highlights the commercial strength of our go-to-market strategy, where a robust, evidence-based scientific foundation is driving initial national-scale clinical adoption.”

Dr Khalid Benhassan, Director of the Mohammed VI National Center for the Disabled, commented:

“Morocco’s national initiative in support of autism, carried out as part of the collaboration between Morocco and the BlinkLab program, reflects a strong and compassionate commitment to promoting early screening and ensuring equitable access to care and appropriate support. As BlinkLab continues its international expansion strategy, this partnership demonstrates how a scientifically validated, AI-based screening program can be integrated on a large scale within an institutional framework led by public authorities. Thanks to the simplicity and accessibility of smartphone technology, BlinkLab makes early screening from as young as 18 months not only clinically reliable, but also practical and deployable across various healthcare and community settings. This approach provides families and frontline healthcare professionals with direct access to an objective assessment of neurological development.”

Strategic Significance for BlinkLab

Real-world validation: Engagement in a government-led national autism screening and training framework constitutes a significant real-world validation opportunity that complements our ongoing FDA registrational clinical trial program in the US. A successful outcome to these programmes, will provide the clinical validation required to support commercialisation and also the ability of Blinklab’s technology to integrate with national public health systems where scalability, operational reliability, and standardised delivery are fundamental requirements.

Regional and Middle East Expansion: Morocco’s national framework has been explicitly designed with a broader regional outlook, providing a structured, government-endorsed model that can be referenced by other countries across North Africa and the Middle East. These countries collectively are actively investing in digital health transformation within public healthcare systems, including early childhood screening initiatives.

Unprecedented Clinical Adoption: Although the Moroccan program is outside the United States, it remains strategically relevant to BlinkLab’s core US market, clinical adoption pathway, and go-to-market strategy. Large-scale national deployment reinforces BlinkLab’s positioning as a potential population-level screening solution, demonstrating its ability to address capacity constraints, healthcare system bottlenecks, long waitlists, and inequities in access. Success within a national framework further strengthens BlinkLab’s global regulatory and clinical narrative by evidencing real-world implementation and system-level utility. This type of validation is increasingly relevant to regulators, payers, and healthcare systems evaluating adoption following FDA clearance.

Revenue outlook: All program-related costs, including infrastructure, hardware, data storage, and implementation expenses, are to be funded by the Moroccan government and associated Foundation partners. No material capital expenditure is expected to be borne by BlinkLab as part of this initiative. The program is not intended to generate immediate revenue; it is designed to prioritise large-scale adoption and utilisation at this stage. Commercial terms, including pricing and deployment models, are expected to be revisited with Moroccan government stakeholders after any future FDA clearance.

International Expert Participation

BlinkLab’s Managing Director and CEO, Dr Henk-Jan Boele, as well as a member of BlinkLab’s Scientific Advisory Board, Prof Abdeslem El Idrissi, have also been listed as members of the international expert consortium supporting the program’s design and implementation. The consortium will help to oversee the academic and clinical aspects of the postgraduate capability building program within the broader Moroccan initiative, reinforcing BlinkLab’s standing within the global autism and neurodevelopmental research community.

The Material Terms of the Agreement include:

• (Convention): The Agreement is between the Foundation and BlinkLab, and falls within the framework of the Convention.
• (Term): The Agreement has an initial term until 29 August 2028 (which is consistent with the period of the Convention). This is defined as the “Initial Period” within the Agreement.
• (Purpose): During the Initial Period:
  
  • BlinkLab will provide the Foundation with access to BlinkLab's smartphone-based neurobehavioural assessments to diagnose autism;
    
  • BlinkLab will provide the Foundation free access (during the Initial Period only) to its application for conducting neurobehavioural assessments on mobile devices for autism as well as expertise, technical support, and training for designated staff at participating centres, which may include initial training sessions and reasonable ongoing support throughout the term of this Agreement to support the objectives of the Agreement; and
  • correspondingly, the Foundation will bear the costs related to local implementation, data hosting costs, data transfer, and the acquisition and installation of equipment and devices necessary for the implementation of the screening program.
• (Intellectual Property): Each party retains all rights, title and interest in and to its respective intellectual property. To the extent that the Foundation makes improvements to BlinkLab’s intellectual property (“Improvements”), the Foundation assigns to BlinkLab all rights, title and interest in and to such Improvements. For the avoidance of doubt, BlinkLab retains all rights, title and interest in, and to, any data generated (either by the Foundation or BlinkLab)via the use of BlinkLab’s platform. Any intellectual property developed (including but not limited to, any enhancements or Improvements), conceived, created, developed or implemented, as a direct result of the Agreement will be the property of BlinkLab.
• (Termination): either BlinkLab or the Foundation can terminate the Agreement (without reasons) by providing not less than 60 days’ written notice to the other party.
• (Further Agreement): Upon expiry of the Initial Period, the parties will (in good faith and using best endeavours) review, discuss and negotiate new terms (including, but not limited to any associated fees to be paid to BlinkLab going forward) with respect to a new agreement, for continued access to BlinkLab’s platform.

The Agreement otherwise contains terms and conditions that are considered standard for an agreement of this nature.

This announcement is intended to lift the trading halt of the Company’s securities, applied for and granted on 19 March 2026.

This announcement has been authorised for release by the Board of BlinkLab Limited.

References

1. ASX Announcement (19 November 2024) – “Large-Scale Study Validates and Enhances BlinkLab’s Accuracy in Detecting Autism in Children”
2. ASX Announcement (19 November 2024) – “Large-Scale Study Validates and Enhances BlinkLab’s Accuracy in Detecting Autism in Children”
3. ASX Announcement (5 January 2026) – “High-Profile Journal Publication Validates BlinkLab’s Technology and Provides Support forFuture Clinical Adoption”
4. Gultig et al. (2026) Neurobehavioral Assessment of Sensorimotor Function in Autism Using Smartphone Technology; Autism Research 19, no. 2: e70166; https://doi.org/10.1002/aur.70166.
5. Zbiri et al. (2024) Private hospitals in low- and middle-income countries: a typology using the cluster method, the case of Morocco; BMC Health Serv Res 24, 1231; https://doi.org/10.1186/s12913-024-11660-2
6. https://dataresearch.ndis.gov.au/reports-and-analyses/participant-dashboards/autism